DNA Replication Licensing and Progenitor Numbers Are Increased by Progesterone in Normal Human Breast
Overview
Authors
Affiliations
Proliferation in the nonpregnant human breast is highest in the luteal phase of the menstrual cycle when serum progesterone levels are high, and exposure to progesterone analogues in hormone replacement therapy is known to elevate breast cancer risk, yet the proliferative effects of progesterone in the human breast are poorly understood. In a model of normal human breast, we have shown that progesterone increased incorporation of 5-bromo-2'-deoxyuridine and increased cell numbers by activation of pathways involved in DNA replication licensing, including E2F transcription factors, chromatin licensing and DNA replication factor 1 (Cdt1), and the minichromosome maintenance proteins and by increased expression of proteins involved in kinetochore formation including Ras-related nuclear protein (Ran) and regulation of chromosome condensation 1 (RCC1). Progenitor cells competent to give rise to both myoepithelial and luminal epithelial cells were increased by progesterone, showing that progesterone influences epithelial cell lineage differentiation. Therefore, we have demonstrated that progesterone augments proliferation of normal human breast cells by both activating DNA replication licensing and kinetochore formation and increasing bipotent progenitor numbers.
A molecular toolbox to study progesterone receptor signaling.
Aarts M, Wagner M, van der Wal T, van Boxtel A, van Amerongen R J Mammary Gland Biol Neoplasia. 2023; 28(1):24.
PMID: 38019315 PMC: 10687192. DOI: 10.1007/s10911-023-09550-0.
Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.
PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.
Morato A, Accornero P, Hovey R J Mammary Gland Biol Neoplasia. 2023; 28(1):10.
PMID: 37219601 PMC: 10205859. DOI: 10.1007/s10911-023-09538-w.
Unexplored Functions of Sex Hormones in Glioblastoma Cancer Stem Cells.
Lee J, Troike K, Fodor R, Lathia J Endocrinology. 2022; 163(3).
PMID: 35023543 PMC: 8807164. DOI: 10.1210/endocr/bqac002.
Trott J, Schennink A, Horigan K, Lemay D, Cohen J, Famula T Endocrinology. 2021; 163(3).
PMID: 34918063 PMC: 10409904. DOI: 10.1210/endocr/bqab256.